Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Key facts

Sponsor

Fred Hutchinson Cancer Center

Principal Investigator

Bart Scott

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Intervention

total-body irradiation(radiation)

Enrollment

25 enrolled

Eligibility

65 years · All sexes

Timeline

2006 – 2014

Study locations (8)

• HealthOne Presbyterian St. Lukes Medical Center, Denver, Colorado, United States
• Emory University, Altanta, Georgia, United States
• Weill Cornell University, New York, New York, United States
• University of Utah, Salt Lake City, Utah, United States
• Veterans Administration Center-Seattle, Seattle, Washington, United States
• Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
• Medical College Wisconsin, Milwaukee, Wisconsin, United States
• Technical University Dresden, Dresden, Saxony, Germany

Collaborators

National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute myeloid leukaemia with myelodysplasia-related features

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT04802161
  Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
  National Cancer Institute (NCI)
• RECRUITINGNCT01210274
  Characterization of the Mechanisms of Resistance to Azacitidine
  Centre Hospitalier Universitaire de Nice

See all trials for Acute myeloid leukaemia with myelodysplasia-related features →